Allos' Folotyn falls at EU regulator: casts doubt over future US sales
This article was originally published in Scrip
Executive Summary
On 19 January 2012, the Committee for Medicinal Products for Human Use (CHMP) recommended that the European Medicines Agency refuse a marketing authorisation for Allos Therapeutics' folate analogue, Folotyn (pralatrexate), a designated orphan product for treating peripheral T-cell lymphoma (PTCL).